RANI THERAPEUTICS HOLDINGS-A (RANI) Forecast, Price Target & Analyst Ratings
NASDAQ:RANI • US7530181004
1.38 USD
+0.02 (+1.47%)
At close: Mar 3, 2026
1.32 USD
-0.06 (-4.35%)
Pre-Market: 3/4/2026, 8:04:44 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RANI THERAPEUTICS HOLDINGS-A (RANI).
Forecast Snapshot
Consensus Price Target
$9.44
+ 583.70% Upside
Next Earnings Forecast
Release DateMar 25, 2026
PeriodQ4 / 2025
EPS Estimate-$0.07
Revenue Estimate5.1M
ChartMill Buy Consensus
82.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.44
Upside
+ 583.70%
From current price of $1.38 to mean target of $9.44, Based on 9 analyst forecasts
Low
$7.07
Median
$9.69
High
$11.55
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
9 analysts have analysed RANI and the average price target is 9.44 USD. This implies a price increase of 583.7% is expected in the next year compared to the current price of 1.38.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
RANI was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about RANI.
In the previous month the buy percentage consensus was at a similar level.
RANI was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-20 | Maxim Group | Maintains | Buy -> Buy |
| 2025-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-02-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-02 | Oppenheimer | Initiate | Outperform |
| 2024-06-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-14 | Maxim Group | Initiate | Buy |
| 2024-06-13 | Rodman & Renshaw | Initiate | Buy |
| 2024-05-09 | BTIG | Maintains | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-27 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-06 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-21 | B of A Securities | Maintains | Buy -> Buy |
| 2023-08-17 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 25, 2026
PeriodQ4 / 2025
EPS Estimate-$0.07
Revenue Estimate5.1M
Revenue Q2Q396.11%
EPS Q2Q74.81%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
RANI is expected to report earnings on 3/25/2026. The consensus EPS estimate for the next earnings is -0.07 USD and the consensus revenue estimate is 5.10M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 1.028M | 5.29M 414.59% | 6.885M 30.15% | 11.998M 74.26% | 34.638M 188.70% | 65.7M 89.68% | 168.06M 155.80% | 379.12M 125.59% | 577.34M 52.28% | 807.67M 39.90% | ||
| EBITDA YoY % growth | -62.9M -23.09% | -65.277M -3.78% | -48.572M 25.59% | -53.857M -10.88% | -58.051M -7.79% | -60.954M -5.00% | -33.603M 44.87% | 501.84K 101.49% | 112.16M 22,249.75% | 313.38M 179.40% | 529.44M 68.95% | N/A | |
| EBIT YoY % growth | -63.45M -22.97% | -66.099M -4.17% | -49.6M 24.96% | -35.745M 27.93% | -39.496M -10.49% | -44.305M -12.18% | -39.915M 9.91% | -19.883M 50.19% | 53.137M 367.25% | 228.51M 330.04% | 399.47M 74.82% | 625.76M 56.65% | |
| Operating Margin | N/A | N/A | -4,824.90% | -675.71% | -573.65% | -369.27% | -115.23% | -30.26% | 31.62% | 60.27% | 69.19% | 77.48% | |
| EPS YoY % growth | -1.28 26.33% | -1.33 -3.91% | -1.06 20.30% | -0.46 56.70% | -0.28 40.00% | -0.29 -4.63% | -0.48 -66.37% | -0.45 5.32% | -0.14 68.54% | 0.64 550.00% | 1.06 65.08% | 1.57 48.08% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 74.81% | -0.09 60.59% | -0.10 46.17% | -0.10 15.00% | -0.15 -124.99% |
| Revenue Q2Q % growth | 5.1M 396.11% | 2.295M 1,234.30% | 2.295M | 2.295M | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.033M 28.56% | -8.099M 32.58% | -9.237M 12.07% | -10.542M -45.26% | -15.81M -96.83% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
20.00%
EPS Next 5 Year
9.47%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-5.54%
EBIT Next 5 Year
14.98%
RANI THERAPEUTICS HOLDINGS-A / RANI Forecast FAQ
What do analysts expect the price target to be for RANI THERAPEUTICS HOLDINGS-A (RANI)?
9 analysts have analysed RANI and the average price target is 9.44 USD. This implies a price increase of 583.7% is expected in the next year compared to the current price of 1.38.
When does RANI THERAPEUTICS HOLDINGS-A (RANI) report earnings?
RANI THERAPEUTICS HOLDINGS-A (RANI) will report earnings on 2026-03-25, after the market close.
Can you provide the consensus estimates for RANI THERAPEUTICS HOLDINGS-A next earnings?
The consensus EPS estimate for the next earnings of RANI THERAPEUTICS HOLDINGS-A (RANI) is -0.07 USD and the consensus revenue estimate is 5.10M USD.
How do analysts rate RANI THERAPEUTICS HOLDINGS-A (RANI)?
The consensus rating for RANI THERAPEUTICS HOLDINGS-A (RANI) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.